The selected article could not be found. Try again later or contact administrator.
Clinical cardiology
Psoriasis and CAD: New call to recognize link
Jan 5, 2009 10:00 EST
A new report is reiterating the increased risk of coronary artery disease observed in patients with the inflammatory skin disease psoriasis and stressing that patients must be informed of this link and have their cardiovascular risk factors regularly assessed and, if necessary, treated. (Friedewald VE et al. Am J Cardiol 2008; 102:1631-43.)
Arrhythmia/EP
No antiarrhythmic protection with fish oil, new meta-analysis shows
Jan 5, 2009 16:45 EST
The analysis, driven primarily by the results of two large clinical trials, showed that fish oil was associated with a significant 20% reduction in the risk of cardiac death but did not reduce the incidence of appropriate ICD interventions or sudden cardiac death. (León H et al. BMJ 2009; published online before print December 23, 2008.)
Clinical cardiology
One in 25 US adults at risk for serious drug-drug interactions, mostly due to CV agents
Dec 31, 2008 13:30 EST
More than two million older US adults may be at risk of adverse events because they frequently take their prescription medications—most of them CV drugs—in dangerous combinations, along with OTC medications and dietary supplements, new survey data suggest. (Qato DM et al. JAMA 2008; 300:2867-2878.)
Lipid/Metabolic
Heart-failure risk climbs with increasing body weight, even for the "preobese"
Dec 29, 2008 10:15 EST
The risk was very high for the obese but was still increased by about half for participants of the Physician's Health Study who were only "overweight." (Kenchaiah S et al. Circulation; published online before print December 22, 2008.)
View all »
Editorial series
A series of discussions among editorial leaders, developed by theheart.org

HeartWire clips
Face-to-face with Dr Melissa Walton-Shirley: From the AHA with Dr Sidney Smith
3 COMMENTS - Dec 16, 2008 13:00 EST
Join theheart.org's forum moderator in these in-depth interviews filmed on location at major congresses
Cardiology panels
Beyond COURAGE
Dec 12, 2008 17:00 EST
Join Drs Harrington, Stone, and Weintraub as they discuss the world of revascularization from COURAGE and beyond, including lessons learned from SYNTAX and FAME, and the questions they hope will be answered by the ongoing PROSPECT trial.
Editorial series
Lipid lowering: The end or the means?
2 COMMENTS - Dec 9, 2008 16:46 EST
Dr Blumenthal talks to Drs Krumholz, Ridker, and Smith about how to approach target guidelines for LDL in the wake of JUPITER, SEARCH, and other lipid-lowering studies.
Cardiology panels
Cardiovascular implications of treating type 2 diabetes, post-APPROACH
Dec 3, 2008 09:30 EST
How best to treat patients presenting with both coronary disease and diabetes? Join Drs Nesto and Fonseca on this rather slippery slope as they examine the data and provide practical guidance for treatment.
Discussion and opinions
Lively, interactive exchanges moderated by thought leaders, staff or contributors to theheart.org

THE BOB HARRINGTON SHOW
Episode #5: ATLAS ACS-TIMI 46 trial and antithrombotic therapy with Dr Gibson
Dec 3, 2008 16:31 EST
Topolog
Reflections on 25 years of cardiology meetings
Dec 3, 2008 09:59 EST
Fellows' Corner
Residents need more sleep?
Dec 3, 2008 09:33 EST
THE CLOTBLOG
The surgeon general issues a call to action to prevent pulmonary embolism and DVT
Dec 16, 2008 14:22 EST
FROM THE CONVENTION FLOOR WITH DR WALTON-SHIRLEY
Complete coverage from the major cardiology meetings
May 14, 2008 15:43 EDT
theHeart.org Discussion Forum
Discussion Forum
May 14, 2008 15:52 EDT
theheart.org Forum, where discussions among healthcare providers, clinicians, and researchers reflect our common goal of decreasing cardiovascular morbidity and mortality around the world.
Lipid/Metabolic
Debate about ezetimibe not over yet: Experts again weigh in on cancer risk
3 COMMENTS - Jan 7, 2009 18:00 EST
At the heart of an exchange in the New England Journal of Medicine between Dr Steven Nissen and Dr Rory Collins and Sir Richard Peto is whether or not a conclusion can be made that there is "no credible evidence" regarding a cancer risk associated with ezetimibe. (Nissen SE. N Engl J Med 2009; 360:86-87; author reply 87.)
Arrhythmia/EP
Federal judge tosses Sprint Fidelis lawsuits
2 COMMENTS - Jan 7, 2009 17:15 EST
The FDA device review and approval process preempts product liability suits filed under state law, according to the decision.
Prevention
Smoking still takes a heavy toll in China
1 COMMENT - Jan 7, 2009 17:00 EST
UPDATED WITH COMMENTARY // A new study has found that smoking continues to be a major risk factor for mortality in China, with almost 700 000 premature deaths estimated to be attributable to tobacco use in 2005. (Gu D et al. N Engl J Med 2009; 360:150-159.)
Acute Coronary Syndrome
MI reduction after smoking ban is sustained over long term
1 COMMENT - Jan 7, 2009 11:00 EST
The reduction in MI hospitalizations observed after a smoke-free law takes effect appears to be sustained over an extended period, according to a new study. (Alsever RN et al. MMWR Morb Mortal Wkly Rep 2009; 57; 1373-1377.)
Arrhythmia/EP
Plastic-friendly IV amiodarone preparation gets FDA approval
Jan 7, 2009 09:15 EST
Acute Coronary Syndrome
Greater use of reperfusion therapy and faster reperfusion times with prehospital ECGs
Jan 6, 2009 18:00 EST
Although prehospital screening translates into improvements in reperfusion for STEMI patients, only one in four patients transported to the hospital by emergency medical services receives a prehospital electrocardiogram. (Diercks DB et al. J Am Coll Cardiol 2009; 53:161-166.)
Interventional/Surgery
New appropriateness guidelines for revascularizations offer help for 180 possible scenarios
Jan 6, 2009 17:15 EST
The document comes amid growing debate over when physicians should or should not move ahead with either PCI or surgery. (Patel MR et al. J Am Coll Cardiol; published online before print January 5, 2009.)
Hypertension
Could an orange a day keep BP down?
Jan 6, 2009 13:15 EST
A new observational study suggests that vitamin C may favorably influence blood pressure in healthy young adults. While the lead researcher recognizes that a randomized trial will be needed to convince people that this is the case, she says there is no harm in encouraging a good diet or in advocating a multivitamin a day in those with poor diets. (Block G et al. Nutrition J; published online before print December 17, 2008.)
Acute Coronary Syndrome
Prasugrel FDA hearing set for February 3, 2009
Dec 31, 2008 15:30 EST
An FDA advisory committee will review prasugrel for the treatment of ACS patients who are managed with PCI on February 3, 2009. Separately, the FDA has also said it may consider changing the label for clopidogrel following studies published last week that show it might not be effective in up to 30% of patients.
Hypertension
CAFE-LLA: Statin therapy does not influence central aortic pressure or hemodynamics
Dec 30, 2008 18:00 EST
Although statins have been shown to have beneficial clinical effects in hypertensive patients, researchers state the "favorable effects are via mechanisms that are independent of important effects on large-artery function and central pressure." (Williams B et al. Circulation 2009; 119:53-61.)
Hypertension
Bosentan in CTEPH trial published, but approval unlikely
Dec 30, 2008 14:00 EST
The medical treatment of inoperable chronic thromboembolic pulmonary hypertension looks set to be confined to off-label therapy for the foreseeable future. Despite the recent publication of the only rigorously conducted trial of any drug in this specific indication, the company says it will not file for this indication. (Jais X et al. J Am Coll Cardiol 2008; 52:2127-2134.)
quote
Psoriasis is one piece of the puzzle and may hold the key to unlocking a lot of the mysteries about coronary disease.
— Dr Vincent E Friedewald
Most popular news
  1. One in 10 stops taking clopidogrel because of "nuisance bleeding"
  2. Genetic variant linked with worse clinical outcomes in MI patients treated with clopidogrel
  3. Prasugrel FDA hearing set for February 3, 2009
  4. Heart-failure risk climbs with increasing body weight, even for the "preobese"
  5. Bosentan in CTEPH trial published, but approval unlikely
  6. First MRA contrast agent approved by the FDA
  7. Doubt cast on reliability of tissue-Doppler imaging for intracardiac pressure estimation
  8. Death, repeat revascularization rates for DES and bare-metal stents similar at three years
  9. CAFE-LLA: Statin therapy does not influence central aortic pressure or hemodynamics
  10. Another reason to get 40 winks? Reduced CAC
Poll
Will you start high-risk patients with hypertension on combination ACE inhibitor and calcium channel blocker therapy?

Yes
No

Vote
button
buttonbutton
button
Previews
View all CME programs >>
View all »
Info from Industry
Features
Editorial series
Lipid lowering: The end or the means?
2 COMMENTS - Dec 9, 2008 16:46 EST
Dr Blumenthal talks to Drs Krumholz, Ridker, and Smith about how to approach target guidelines for LDL in the wake of JUPITER, SEARCH, and other lipid-lowering studies.
The Cardiology Show
AHA 2008: The AHA Flies to JUPITER
3 COMMENTS - Nov 14, 2008 12:00 EST
Join Drs Krumholz, Blumenthal, Harrington, Jessup, Ridker, Smith, Stone, Weintraub, and Yancy as they dissect the results of the JUPITER and debate the far-reaching clinical implications of this landmark study in Part 1 of the program. In Part 2, the panelists look at the positive sides of HF-Action and TIMACS and deliberate the real lessons learned from these negative trials.